Abstract
Study Design Integrated preclinical systematic review and meta-analysis with basic experimental research. Objectives To evaluate the therapeutic efficacy of miR-124-3p in spinal cord injury (SCI) repair and elucidate its mechanism involving the CTDSP1/WNT/β‑catenin axis. Setting University-based laboratory in Lanzhou, China. Methods A meta‑analysis of five animal studies assessed the effects of miR‑124‑3p. In vitro, a lipopolysaccharide‑injured PC12 cell model was treated with exosomes derived from miR‑124‑3p‑overexpressing human umbilical cord mesenchymal stem cells. Mechanistic validation included dual‑luciferase reporter assay, qPCR, Western blot, and pathway inhibition/rescue experiments. Results The meta‑analysis showed that miR‑124‑3p significantly improved motor function, reduced glial scar marker GFAP and pro‑inflammatory cytokines, and increased neuronal/axonal markers (Map2, NF200, NeuN). Mechanistically, miR‑124‑3p directly targeted the 3′‑UTR of CTDSP1. Exosome‑delivered miR‑124‑3p downregulated CTDSP1, activated WNT/β‑catenin signaling, suppressed GFAP/CSPG, and promoted β‑tubulin III, NeuN, and NF200 expression. These effects were reversed by the WNT inhibitor MSAB and mimicked by a CTDSP1 inhibitor. Conclusions miR‑124‑3p promotes SCI repair primarily by targeting CTDSP1 to activate the WNT/β‑catenin pathway, thereby inhibiting glial scarring and enhancing neuronal survival/regeneration. This mechanism supports the therapeutic potential of combined exosome and miRNA strategies. The alternative text for this image may have been generated using AI.

This publication has 30 references indexed in Scilit: